Alimera Sciences Announces 23 Clinical Presentations and a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress

ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from an unprecedented 23 ILUVIEN ® post marketing studies involving more than 450 cases will be presented during the 16th European Society of Retina Specialists Congress (EURETINA), September 8-11, 2016, in Copenhagen. Eight presentations will be given by speakers from the podium, while there will be 15 electronic posters that will be available throughout the meeting for review by EURETINA attendees.

In addition, on Friday, September 9, Alimera will sponsor a symposium as part of the EuroTimes Satellite Education Program. Entitled "Continuous Microdosing with Intravitreal Corticosteroids: A Real-World Perspective in Patients with Chronic DME," the lunchtime event will be moderated by Prof. Francesco Bandello, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy. Panel participants include: Prof. Ramin Tadayoni, Université Paris 7 (Sorbonne Paris Cité) Hôpital Lariboisière, Paris, France; Prof. Frank Koch, Universitäts Klinikum, Frankfurt, Germany; and Dr. Fahd Quhill, Royal Hallamshire Hospital, Sheffield, England.

The scheduled times, titles and locations of the eight speaker presentations are as follows:

  • U. Chakravarthy, C. Bailey, F. Koch, U.K. and Germany Safety and clinical outcomes in the European registry study of ILUVIEN implant (fluocinolone acetonide; FAc) usage in diabetic macular edema, Thursday, September 8, 11:00 a.m., Auditorium A2.
  • J. Henriques, J. Figueira, M. Amaro, V. Rosas, Portugal Structural and functional outcomes of lens status in patients with chronic Diabetic Macular Edema (DME) treated with the ILUVIEN implant (0.2 mcg/day fluocinolone acetonide): Results from the RESPOND trial, Thursday, September 8, 12:12 p.m., Auditorium A2.
  • Elaraoud, Y. Yang, J. Maya, N. Narendran, C. Bailey, A. Lotery, Y. Yang, U.K. Efficacy assessment of ILUVIEN (0.2 mcg/d fluocinolone acetonide) using the area-under-the-curve method, Friday, September 9, 8:42 a.m., Auditorium C6.
  • H. Bayat, L. Makris, M. Loutfi, A. Kamal, U.K. Initial experience of ILUVIEN intravitreal implant (190 micrograms fluocinolone acetonide) in the management of chronic diabetic macular oedema (DME) in a real clinical setting, Friday, September 9, 2:36 p.m., Auditorium 15.
  • F. Alfaqawi, S. Elsherbiny, P. Lip, B. Mushtaq, U.K. Fluocinolone acetonide intravitreal implant (ILUVIEN) as the treatment for chronic diabetic macular oedema in a real-world clinical practice in the UK: 18-month results, Friday, September 9, 4:30 p.m., Auditorium A3.
  • A. Brent, S. Ch'ng, T. Empeslidis, V. Konidaris, S. Banerjee, U.K. 2 year results from a prospective on-going audit of ILUVIEN outcomes for diabetic macular oedema (DMO), Saturday, September 10, 8:48 a.m., Auditorium C6.
  • C. Bailey, U. Chakravarthy, J. Cunha-Vaz,C. Wykoff, U.K. Evaluation of diabetic retinopathy progression with chronic diabetic macular edema (DME) patients treated with ILUVIEN (0.2 mcg/d), Saturday, September 10, 4:36 p.m., Auditorium 10.
  • P. Richardson, P. Wright, UK Fluocinolone acetonide intravitreal implantation for chronic diabetic macular oedema: 12 months clinical data, Saturday, September 10, 5:42 p.m., Auditorium 10.     

About ILUVIEN

www.ILUVIEN.com .

ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.

ILUVIEN'S E.U. Indication

ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera Sciences (NASDAQ: ALIM ), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit  www.alimerasciences.com .

For press inquiries: Katie Brazel for Alimera Sciences 404-317-8361 kbrazel@bellsouth.net For investor inquiries: CG Capital for Alimera Sciences 877-889-1972 investorrelations@cg.capital

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 204

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 180

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 61

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 182

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 191

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Coloplast A/S Highlights Impressive Full-Year Performance

Updated Category News Views 231

Coloplast A/S Financial Results Overview Coloplast A/S recently announced its full-year financial results for the fiscal year 2023/24, highlighting a solid performance characterized by growth and resilience across various business sectors. Their latest report demonstrates a robust organic growth rate of 8%, coupled with a notable EBIT margin of 27%. In monetary terms, the...

Continue Reading
Introducing Sproutr’s Innovative Program Placement Services

Updated Category News Views 200

Sproutr Unveils Comprehensive Program Placement Services Sproutr, a leading firm in insurance program design and product development, has launched its innovative Program Placement Services. This new offering aims to streamline the entire process of insurance program development, ensuring that it aligns well from the initial design to the final placement with carriers. The...

Continue Reading
Unstoppable Domains Introduces .DEMOS: Redefining Digital Identity

Updated Category News Views 147

Introducing .DEMOS: A New Era of Digital Identity In an exciting development, Unstoppable Domains has rolled out a new top-level domain, .DEMOS, in collaboration with Kynesys.xyz. This innovative domain is positioned as a Web3-first solution designed to foster connection and collaboration in a borderless internet landscape. The name .DEMOS is derived from the Greek term...

Continue Reading
Investors Urged to Join Class Action Against Open Lending Corporation

Updated Category News Views 193

Open Lending Corporation: A Call to Action for Affected Investors Investors suffering heavy losses in Open Lending Corporation (NASDAQ: LPRO) are presented with the chance to take action. It's an opportunity for those impacted by the recent financial discrepancies and corporate disclosures to become lead plaintiffs in a class action lawsuit. Class Action Lawsuit Details...

Continue Reading
McAfee Revolutionizes Digital Security with AI Techniques

Updated Category News Views 253

Innovative Protection: McAfee Leads in AI-Powered Security Recognized as a leader in online security, McAfee has become synonymous with consumer safety in a rapidly evolving digital landscape. With the escalation of online threats, including sophisticated deepfakes and scams, McAfee's advanced artificial intelligence capabilities make it the prime choice for individuals...

Continue Reading